Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Jan;48(1):26–32. doi: 10.1136/jcp.48.1.26

Cytokeratin intermediate filament expression in benign and malignant breast disease.

M Heatley 1, P Maxwell 1, C Whiteside 1, P Toner 1
PMCID: PMC502256  PMID: 7535804

Abstract

AIM--To carry out a comprehensive study of cytokeratin expression in benign and malignant breast epithelium and breast myoepithelial cells; to examine changes in the cytokeratin profile in malignant and benign epithelium and in carcinomas of increasing histological grade. METHODS--Frozen sections from fibroadenomas (19 cases), fibrocystic disease (19 cases), and infiltrating ductal (68 cases), lobular (seven cases), and mucinous carcinomas (three cases) were examined using a panel of monoclonal antibodies. RESULTS--The luminal epithelium in all fibroadenomas and all cases of fibrocystic disease, as well as tumour cells in most carcinomas, reacted with the specific antibodies to cytokeratins 7, 8, 18, and 19 and to antibodies which included these cytokeratins in their specificities (Cam 5.2, AE1, AE3, RCK102, and LP34). In a few ductal carcinomas none of the tumour cells reacted for cytokeratins 7, 8, or 18. Three ductal carcinomas expressed cytokeratin 14. Only occasional cases expressed cytokeratins 3, 4, 10, and 13. Antibodies which included cytokeratins 5 and 14 in their specificities detected myoepithelial cells less efficiently than antiactin antibodies. CONCLUSION--The cytokeratin profiles in the luminal epithelium in benign breast disease and in tumour cells in most carcinomas are similar in most cases. Some carcinomas, however, are negative for cytokeratins 7, 8, or 18. This may provide a means of predicting the biological behaviour of a histologically borderline lesion.

Full text

PDF
26

Images in this article

27Image
on p.27
28Image
on p.28
28Image
on p.28
28Image
on p.28
29Image
on p.29
31Image
on p.31

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartek J., Taylor-Papadimitriou J., Miller N., Millis R. Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. Int J Cancer. 1985 Sep 15;36(3):299–306. [PubMed] [Google Scholar]
  3. Battifora H. Clinical applications of the immunohistochemistry of filamentous proteins. Am J Surg Pathol. 1988;12 (Suppl 1):24–42. [PubMed] [Google Scholar]
  4. Broers J. L., Ramaekers F. C., Rot M. K., Oostendorp T., Huysmans A., van Muijen G. N., Wagenaar S. S., Vooijs G. P. Cytokeratins in different types of human lung cancer as monitored by chain-specific monoclonal antibodies. Cancer Res. 1988 Jun 1;48(11):3221–3229. [PubMed] [Google Scholar]
  5. Bártek J., Vojtesek B., Stasková Z., Bártková J., Kerekés Z., Rejthar A., Kovarík J. A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology. J Pathol. 1991 Jul;164(3):215–224. doi: 10.1002/path.1711640306. [DOI] [PubMed] [Google Scholar]
  6. Corson J. M. Keratin protein immunohistochemistry in surgical pathology practice. Pathol Annu. 1986;21(Pt 2):47–81. [PubMed] [Google Scholar]
  7. Dairkee S. H., Ljung B. M., Smith H., Hackett A. Immunolocalization of a human basal epithelium specific keratin in benign and malignant breast disease. Breast Cancer Res Treat. 1987 Oct;10(1):11–20. doi: 10.1007/BF01806130. [DOI] [PubMed] [Google Scholar]
  8. Dairkee S. H., Puett L., Hackett A. J. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue. J Natl Cancer Inst. 1988 Jul 6;80(9):691–695. doi: 10.1093/jnci/80.9.691. [DOI] [PubMed] [Google Scholar]
  9. Domagala W., Lubinski J., Weber K., Osborn M. Intermediate filament typing of tumor cells in fine needle aspirates by means of monoclonal antibodies. Acta Cytol. 1986 May-Jun;30(3):214–224. [PubMed] [Google Scholar]
  10. Elston C. W., Gresham G. A., Rao G. S., Zebro T., Haybittle J. L., Houghton J., Kearney G. The cancer research campaign (King's/Cambridge trial for early breast cancer: clinico-pathological aspects. Br J Cancer. 1982 May;45(5):655–669. doi: 10.1038/bjc.1982.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ferrero M., Spyratos F., Le Doussal V., Desplaces A., Rouëssé J. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors. Cytometry. 1990;11(6):716–724. doi: 10.1002/cyto.990110609. [DOI] [PubMed] [Google Scholar]
  12. Gottlieb C., Raju U., Greenwald K. A. Myoepithelial cells in the differential diagnosis of complex benign and malignant breast lesions: an immunohistochemical study. Mod Pathol. 1990 Mar;3(2):135–140. [PubMed] [Google Scholar]
  13. Gould V. E., Koukoulis G. K., Jansson D. S., Nagle R. B., Franke W. W., Moll R. Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast. Am J Pathol. 1990 Nov;137(5):1143–1155. [PMC free article] [PubMed] [Google Scholar]
  14. Guelstein V. I., Tchypysheva T. A., Ermilova V. D., Litvinova L. V., Troyanovsky S. M., Bannikov G. A. Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int J Cancer. 1988 Aug 15;42(2):147–153. doi: 10.1002/ijc.2910420202. [DOI] [PubMed] [Google Scholar]
  15. Gusterson B. A., Warburton M. J., Mitchell D., Ellison M., Neville A. M., Rudland P. S. Distribution of myoepithelial cells and basement membrane proteins in the normal breast and in benign and malignant breast diseases. Cancer Res. 1982 Nov;42(11):4763–4770. [PubMed] [Google Scholar]
  16. Lehto V. P., Miettinen M., Virtanen I. Antibodies to intermediate filaments in surgical pathology. Arch Geschwulstforsch. 1986;56(4):283–298. [PubMed] [Google Scholar]
  17. Moll R., Schiller D. L., Franke W. W. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990 Aug;111(2):567–580. doi: 10.1083/jcb.111.2.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mørk C., van Deurs B., Petersen O. W. Regulation of vimentin expression in cultured human mammary epithelial cells. Differentiation. 1990 Apr;43(2):146–156. doi: 10.1111/j.1432-0436.1990.tb00441.x. [DOI] [PubMed] [Google Scholar]
  19. Nagle R. B., Böcker W., Davis J. R., Heid H. W., Kaufmann M., Lucas D. O., Jarasch E. D. Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem. 1986 Jul;34(7):869–881. doi: 10.1177/34.7.2423579. [DOI] [PubMed] [Google Scholar]
  20. Nagle R. B. Intermediate filaments: a review of the basic biology. Am J Surg Pathol. 1988;12 (Suppl 1):4–16. [PubMed] [Google Scholar]
  21. Osborn M., Weber K. Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest. 1983 Apr;48(4):372–394. [PubMed] [Google Scholar]
  22. Ramaekers F., van Niekerk C., Poels L., Schaafsma E., Huijsmans A., Robben H., Schaart G., Vooijs P. Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas. Am J Pathol. 1990 Mar;136(3):641–655. [PMC free article] [PubMed] [Google Scholar]
  23. Schaafsma H. E., Ramaekers F. C., van Muijen G. N., Lane E. B., Leigh I. M., Robben H., Huijsmans A., Ooms E. C., Ruiter D. J. Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol. 1990 Feb;136(2):329–343. [PMC free article] [PubMed] [Google Scholar]
  24. Smedts F., Ramaekers F., Robben H., Pruszczynski M., van Muijen G., Lane B., Leigh I., Vooijs P. Changing patterns of keratin expression during progression of cervical intraepithelial neoplasia. Am J Pathol. 1990 Mar;136(3):657–668. [PMC free article] [PubMed] [Google Scholar]
  25. Taylor-Papadimitriou J. Immunohistochemical analysis of benign and malignant breast tumours. Pathol Biol (Paris) 1990 Oct;38(8):778–778. [PubMed] [Google Scholar]
  26. Tsubura A., Okada H., Senzaki H., Hatano T., Morii S. Keratin expression in the normal breast and in breast carcinoma. Histopathology. 1991 Jun;18(6):517–522. doi: 10.1111/j.1365-2559.1991.tb01478.x. [DOI] [PubMed] [Google Scholar]
  27. Vojtesek B., Stasková Z., Nenutil R., Bártková J., Kovarík J., Rejthar A., Bártek J. A panel of monoclonal antibodies to keratin no. 7: characterization and value in tumor diagnosis. Neoplasma. 1990;37(3):333–342. [PubMed] [Google Scholar]
  28. Wahli W. Evolution and expression of vitellogenin genes. Trends Genet. 1988 Aug;4(8):227–232. doi: 10.1016/0168-9525(88)90155-2. [DOI] [PubMed] [Google Scholar]
  29. Wetzels R. H., Holland R., van Haelst U. J., Lane E. B., Leigh I. M., Ramaekers F. C. Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast. Am J Pathol. 1989 Mar;134(3):571–579. [PMC free article] [PubMed] [Google Scholar]
  30. Wetzels R. H., Kuijpers H. J., Lane E. B., Leigh I. M., Troyanovsky S. M., Holland R., van Haelst U. J., Ramaekers F. C. Basal cell-specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol. 1991 Mar;138(3):751–763. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES